Statement on SCOTUS Ruling

On July 8, the Supreme Court of the United States (SCOTUS) ruled to uphold the Trump Administration’s regulations allowing employers and insurers to decline providing contraception coverage because of religious or moral objections. Implementation of these rules will immediately and significantly decrease contraceptive access for 70,500 to 126,400 women.

When the rules were implemented in 2017, Medicines360 expressed our strong opposition alongside countless women’s health advocates. Lawsuits were filed, petitions were circulated, and grassroots campaigns were organized in response to this attack on women’s health. This ruling is likely to have an impact more detrimental than we ever imagined.

“We firmly believe that access to affordable contraception shouldn’t depend on whether your boss believes in birth control,” said Jessica Grossman, M.D., CEO of Medicines360. “Unfortunately, today’s Supreme Court decision will do exactly this—undoing years of progress in expanding contraceptive coverage.”

As a nonprofit pharmaceutical organization that makes our hormonal IUD available through safety-net clinics, Medicines360 sees the hidden consequences of the Court’s decision.

First, limiting the contraceptive choices available to women detracts from the doctor-patient relationship. This ruling could cause women and their doctors to base their contraceptive decisions on factors that shouldn’t be involved, such as a method’s eligibility to be covered by insurance. This is problematic because the most effective contraceptive methods are often the most expensive. We must ensure women’s care decisions are patient-centric and based on clinical concerns first and foremost, including sound evidence, careful weighing of the benefits of medicines for patients, and other factors that are best handled between women and their doctors.

Furthermore, the only way to close gaps in access is to ensure not just some, but all people have access to the full range of contraceptive methods. It shouldn’t depend on your employer. These rules undermine equitable access and remove choice.

It’s counterproductive and harmful to uphold these rules, as they hinder the progress we’ve made towards improving women’s access to reproductive health care. Access to contraception and family planning counseling helps improve health outcomes for women and infants. The cost implications of an increase in unplanned pregnancy rates would be profound: our health system would be forced to bear more financial costs, and children, women, families, and communities would become less secure.

Access to contraception helps women attain higher levels of education, more economic success, and healthier families. For young adults, even modest increases in the availability of contraception leads to significant and lasting educational and employment gains for women.

We at Medicines360 work tirelessly to provide affordable, quality medicines to all women and believe these rules simply should not exist in 2020. Why? Because nothing should ever stand in the way of women and the medicines they need.

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.